Targeting The Polyamine Addiction Of Neuroblastoma

Neuroblastoma is the most common solid tumor of early childhood and arises from the primitive cells of the sympathetic nervous system. The survival rates for children with high-risk neuroblastoma are around 50%. Those who do survive are often left with long-term side-effects from the intense, multimodal treatment. Better, targeted therapies are thus urgently needed.

ADVERTISEMENT

Amplification (multiple copies) of the MYCN oncogene is found in 40–50% of high-risk neuroblastomas and is associated with aggressive disease and poor outcome. MYCN belongs to the MYC family of transcription factors, which play critical roles in many of the cellular processes required for tumorigenesis. To date, no drugs have been found that can effectively inhibit MYCN, so many scientists are focusing their attention on its transcriptional targets.

One of the first and best-characterized of these targets is ornithine decarboxylase (ODC1). Catalyzing the decarboxylation and conversion of ornithine to the primary polyamine putrescine, ODC1 is the first enzyme in the polyamine pathway. Polyamines (putrescine, spermidine, and spermine) are multifunctional polycations that are essential for cell growth, differentiation, and survival. They are elevated in rapidly proliferating cells, and the association between increased polyamines and tumor formation is well established.

A highly potent, specific, irreversible inhibitor of ODC1, α-difluoromethylornithine (DFMO; also known as eflornithine), was developed in 1978. DFMO is approved for the treatment of West African Sleeping Sickness (trypanosomiasis) and patients with excessive facial hair. While it shows promise as an anti-cancer agent — decreasing intracellular polyamines and inhibiting tumor cell growth in vitro — DFMO as a monotherapy for established tumors has had limited success in clinical trials.

DFMO targets the synthesis of polyamines, however, intracellular polyamine levels are tightly regulated through three main mechanisms. In addition to de novo synthesis, polyamines are broken down by catabolic pathways, and can also be taken up through transporters in the cell membrane. Our latest research demonstrates that MYCN up- or down-regulates genes known to be involved in the entire polyamine pathway — raising polyamine levels in high-risk neuroblastoma through all three mechanisms.

ADVERTISEMENT

We also provide strong evidence that a solute carrier called SLC3A2 is the main polyamine transporter in neuroblastoma cells. Cells treated with DFMO (to block polyamine synthesis) increased their amount of SLC3A2 transporter and their uptake of the radiolabeled polyamine spermidine. This increase in SLC3A2 did not occur when MYCN was silenced, indicating that SLC3A2 is also a transcriptional target of MYCN.

Because polyamine uptake from the microenvironment provides a rescue pathway for polyamine-addicted tumor cells, we examined the effects of simultaneously inhibiting polyamine synthesis and blocking polyamine transport. To block polyamine transport, we used an inhibitor called AMXT-1501, which we demonstrated completely prevented the uptake of radiolabeled spermidine in multiple neuroblastoma cell lines. Importantly, we found that AMXT-1501 also prevented the compensatory increase in polyamine uptake observed upon treatment with DFMO.

1) Cancer cells synthesize polyamines but can also take up dietary polyamines from the microenvironment; 2) DFMO blocks polyamine synthesis, but cells increase their polyamine uptake to compensate; 3) AMXT-1501 blocks polyamine uptake, and in combination with DFMO profoundly depletes intracellular polyamines. ODC1: ornithine decarboxylase. Figure courtesy Claudia Flemming.

In vitro, the combination of DFMO and AMXT-1501 synergistically inhibited neuroblastoma cell growth. In vivo, in an MYCN transgenic mouse model of neuroblastoma, when this drug combination was administered before tumor formation, it either prevented tumor formation altogether (in 40% of mice) or extended survival time (in 60% of mice). The combination also significantly extended survival time when given to mice with established tumors.

The combination of DFMO and AMXT-1501 also extended survival in another mouse model, in which mice received human neuroblastoma cells derived from a patient (patient-derived xenograft, or PDX for short).

ADVERTISEMENT

A clinical trial for children with relapsed or refractory neuroblastoma is currently underway (NCT02030964) that combines DFMO with a drug called celecoxib, which can increase polyamine catabolism (breakdown). This combination does not, however, prevent polyamine uptake. Our results indicate that adding a drug like AMXT-1501 to inhibit polyamine uptake warrants clinical investigation in children with MYCN-driven high-risk neuroblastoma.

The first clinical trial of AMXT-1501 in combination with DFMO in adult cancer patients (NCT03536728) has recently opened in the US, bringing its future use for treating children one step closer.

These findings are described in the article entitled Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma, recently published in the journal Science Translational Medicine.

Comments

READ THIS NEXT

Cosmology Of The Higgs Boson

The discovery of the Higgs boson at the CERN Large Hadron Collider in 2012 has deep implications for our universe. […]

Costs And Benefits Of Bioenergy Alternatives For Birds

A predicament the United States faces is the simultaneous threat of climate change and the rising energy demands of its […]

The Formation Of Mars’ Juventae Chasma

Mars is a planet of geological curiosities that often have no parallels on Earth. Among these include the largest and […]

Using Olefin Metathesis To Produce Macrocyclic Products

Molecules containing twelve or more atoms within at least one large ring are called macrocyclic compounds or macrocycles. At the beginning of […]

Record Low Voltage Losses In Efficient Cascade Organic Solar Cells

The sun is a limitless energy source, and photovoltaics is the most commonly used technology for converting solar energy into […]

Development Of A Functional Molecule With Fluorescent Properties For High Cholesterol Analogy

Many people are concerned about cholesterol because of high cholesterol levels in their blood. However, cholesterol is crucial for our […]

Can We Maximize The Economic Benefits Of Microalgae Biofuel Production?

An increasing body of research has indicated that microalgae biofuels have the potential to effectively transition society away from fossil […]

Science Trends is a popular source of science news and education around the world. We cover everything from solar power cell technology to climate change to cancer research. We help hundreds of thousands of people every month learn about the world we live in and the latest scientific breakthroughs. Want to know more?